Literature DB >> 33757438

Chinese patients' clinical and psychosocial outcomes in the 6 months following percutaneous coronary intervention.

Xia Liu1, Adeleke Fowokan2, Sherry L Grace3,4, Biao Ding5, Shu Meng6, Xiu Chen6, Yinghua Xia6, Yaqing Zhang1.   

Abstract

BACKGROUND: In China, there has been a precipitous increase in the number of percutaneous coronary interventions (PCI) conducted. We sought to characterize the clinical and psychosocial trajectory of PCI patients from the time of procedure through 6 months post, and correlates of adverse cardiovascular events (ACEs).
METHODS: In this prospective, observational study, patients from 2 hospitals in Shanghai, China were assessed. At follow-up visits at 1, 3 and 6 months post-PCI, clinical indicators were again extracted from patients' clinical records, including ACEs, and they completed validated surveys assessing self-management, as well as psychosocial indicators (Hospital Anxiety and Depression Scale; Pittsburgh Sleep Quality Index; quality of life [QoL]: SF-12, Seattle Angina Questionnaire [SAQ]). Repeated measures analysis of variance, adjusted for Barthel index and PCI indication, was used to assess change over time in risk factors and psychosocial indicators. Logistic regression was used to explore correlates of ACEs.
RESULTS: 610 participants (mean age = 63.3; n = 150, 18.2% female) were recruited, of which 491 (80.5%) were retained at 6 months. 82 (16.7%) had an ACE at any time point, including most commonly angina and stroke (only 1 death). Clinical indicators such as blood pressure (p < 0.031 for both), symptom burden (p < .01 on all subscales) and QoL (p < 0.001 for both, but started quite low) improved over 6 months. Anxiety and depressive symptoms were above threshold, and the latter worsened over time (p < 0.001). With adjustment for age and indication, patients with any ACEs had higher sleep latency (odds ratio [OR] = 1.48; 95% confidence interval [CI] = 1.03-2.10]), and depressive symptoms (OR = 1.20; 95% CI = 1.02-1.41), but lower anxiety (OR = 0.79; 95% CI = 0.67-0.93) compared to those without.
CONCLUSION: Centers may wish to re-visit patient selection criteria and processes for PCI, as well as implement mental health screening and treatment protocols, as can be achieved through cardiac rehabilitation, given how hazardous psychosocial distress is in this population.

Entities:  

Keywords:  Angina; Anxiety disorders; Cardiovascular diseases; Cardiovascular risk factors; China; Depression; Percutaneous coronary intervention; Quality of life; Signs and symptoms; Sleep

Year:  2021        PMID: 33757438     DOI: 10.1186/s12872-021-01954-2

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  20 in total

1.  The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention.

Authors:  Kornelia Kotseva
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

2.  Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.

Authors:  Amit P Amin; Mark Patterson; John A House; Helmut Giersiefen; John A Spertus; Dmitri V Baklanov; Adnan K Chhatriwalla; David M Safley; David J Cohen; Sunil V Rao; Steven P Marso
Journal:  JACC Cardiovasc Interv       Date:  2017-02-27       Impact factor: 11.195

3.  Tracking Cardiac Rehabilitation Participation and Completion Among Medicare Beneficiaries to Inform the Efforts of a National Initiative.

Authors:  Matthew D Ritchey; Sha Maresh; Jessica McNeely; Thomas Shaffer; Sandra L Jackson; Steven J Keteyian; Clinton A Brawner; Mary A Whooley; Tiffany Chang; Haley Stolp; Linda Schieb; Janet Wright
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-01-14

4.  Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis.

Authors:  A Meijer; H J Conradi; E H Bos; M Anselmino; R M Carney; J Denollet; F Doyle; K E Freedland; S L Grace; S H Hosseini; D A Lane; L Pilote; K Parakh; C Rafanelli; H Sato; R P Steeds; C Welin; P de Jonge
Journal:  Br J Psychiatry       Date:  2013-08       Impact factor: 9.319

5.  Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study.

Authors:  Shiwei Liu; Yichong Li; Xinying Zeng; Haidong Wang; Peng Yin; Lijun Wang; Yunning Liu; Jiangmei Liu; Jinlei Qi; Sha Ran; Shiya Yang; Maigeng Zhou
Journal:  JAMA Cardiol       Date:  2019-04-01       Impact factor: 14.676

6.  Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study.

Authors:  Xin Zheng; Jeptha P Curtis; Shuang Hu; Yongfei Wang; Yuejin Yang; Frederick A Masoudi; John A Spertus; Xi Li; Jing Li; Kumar Dharmarajan; Nicholas S Downing; Harlan M Krumholz; Lixin Jiang
Journal:  JAMA Intern Med       Date:  2016-04       Impact factor: 21.873

Review 7.  Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.

Authors:  Daniel M Kolansky
Journal:  Am J Manag Care       Date:  2009-03       Impact factor: 2.229

8.  Role of depression in secondary prevention of Chinese coronary heart disease patients receiving percutaneous coronary intervention.

Authors:  Can Feng; Tao Ji; Yu Liu; Danfeng Chen; Jia Dai; Xiushi Ni; Jiaqi Zhu; Xuebo Liu; Xianxian Zhao
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

9.  Depression in the context of chronic diseases in the United States and China.

Authors:  Hongjin Li; Song Ge; Brian Greene; Jacqueline Dunbar-Jacob
Journal:  Int J Nurs Sci       Date:  2018-11-29

10.  Percutaneous Coronary Intervention in Patients Without Acute Myocardial Infarction in China: Results From the China PEACE Prospective Study of Percutaneous Coronary Intervention.

Authors:  Yuan Lu; Haibo Zhang; Yongfei Wang; Tianna Zhou; John Welsh; Jiamin Liu; Wenchi Guan; Jing Li; Xi Li; Xin Zheng; John A Spertus; Frederick A Masoudi; Harlan M Krumholz; Lixin Jiang
Journal:  JAMA Netw Open       Date:  2018-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.